Research
- Research Topics
- Cell Biology and Tumor Biology
- Stem Cells and Cancer
- Inflammatory Stress in Stem Cells
- Experimental Hematology
- Molecular Embryology
- Signal Transduction and Growth Control
- Epigenetics
- Redox Regulation
- Vascular Oncology and Metastasis
- Clinical Neurobiology
- Molecular Neurogenetics
- Chaperones and Proteases
- Vascular Signaling and Cancer
- Molecular Neurobiology
- Mechanisms Regulating Gene Expression
- Molecular Biology of Centrosomes and Cilia
- Dermato-Oncology
- Pediatric Leukemia
- Tumour Metabolism and Microenvironment
- Personalized Medical Oncology
- Molecular Hematology - Oncology
- Cancer Progression and Metastasis
- Translational Surgical Oncology
- Neuronal Signaling and Morphogenesis
- Cell Signaling and Metabolism
- Cell Fate Engineering and Disease Modeling
- Cancer Drug Development
- Cell Morphogenesis and Signal Transduction
- Functional and Structural Genomics
- Molecular Genome Analysis
- Molecular Genetics
- Pediatric Neurooncology
- Cancer Genome Research
- Chromatin Networks
- Functional Genome Analysis
- Theoretical Systems Biology
- Neuroblastoma Genomics
- Signaling and Functional Genomics
- Signal Transduction in Cancer and Metabolism
- RNA-Protein Complexes and Cell Proliferation
- Systems Biology of Signal Transduction
- Areas of Interest
- Advancement of clinical proteomics for systems medicine
- Bridging from the single cell to the cell population – Epo-induced cellular responses and erythroleukemia
- Deciphering tumor microenvironment interactions determining lung cancer development
- Mechanisms controlling the compensation of liver injury and towards model-based biomarkers for early detection of liver cancer
- Application of dynamic pathway modelling for personalized medicine
- Group Members
- Publications
- Open Positions
- Funding
- Teaching
- Areas of Interest
- Molecular thoracic Oncology
- Proteomics of Stem Cells and Cancer
- Computational Genomics and System Genetics
- Applied Functional Genomics
- Applied Bioinformatics
- Translational Medical Oncology
- Metabolic crosstalk in cancer
- Pediatric Glioma Research
- Cancer Epigenomics
- Translational Pediatric Sarcoma Research
- Artificial Intelligence in Oncology
- Mechanisms of Genomic Variation and Data Science
- Neuropathology
- Pediatric Oncology
- Neurooncology
- Somatic Evolution and Early Detection
- Translational Control and Metabolism
- Soft-Tissue Sarcoma
- Precision Sarcoma Research
- Brain Mosaicism and Tumorigenesis
- Mechanisms of Genome Control
- Translational Gastrointestinal Oncology and Preclinical Models
- Translational Lymphoma Research
- Mechanisms of Leukemogenesis
- Genome Instability in Tumors
- Developmental Origins of Pediatric Cancer
- Brain Tumor Translational Targets
- Translational Functional Cancer Genomics
- Regulatory Genomics and Cancer Evolution
- SPRINT
- Cancer Risk Factors and Prevention
- Cancer Epidemiology
- Biostatistics
- Clinical Epidemiology and Aging Research
- Health Economics
- Physical Activity, Prevention and Cancer
- Preventive Oncology
- Personalized Early Detection of Prostate Cancer
- Digital Biomarkers for Oncology
- Tumorigenesis and molecular cancer prevention
- Genomic Epidemiology
- Cancer Survivorship
- Immunology and Cancer
- Cellular Immunology
- Molecular Oncology of Gastrointestinal Tumors
- Immunoproteomics
- Personalized Immunotherapy
- mRNA Cancer Immunotherapies
- Translational Immunotherapy
- B Cell Immunology
- Immune Diversity
- Structural Biology of Infection and Immunity
- Applied Tumor Immunity
- Neuroimmunology and Brain Tumor Immunology
- Adaptive Immunity and Lymphoma
- Dermal Oncoimmunology
- Immune Regulation in Cancer
- Systems Immunology and Single Cell Biology
- GMP & T Cell Therapy
- Immune Monitoring
- News
- Imaging and Radiooncology
- Radiology
- Research
- Computational Radiology Research Group
- Contrast Agents In Radiology Research Group
- Neuro-Oncologic Imaging Research Group
- Radiological Early Response Assessment Of Modern Cancer Therapies
- Imaging In Monoclonal Plasma Cell Disorders
- 7 Tesla MRI - Novel Imaging Biomarkers
- Functional Imaging
- Visualization And Forensic Imaging
- PET/MRI
- Dual- and Multienergy CT
- Radiomics Research Group
- Prostate Research Group
- Breast Imaging Research Group
- Bone marrow
- Musculoskeletal Imaging
- Microstructural Imaging Research Group
- Staff
- Patients
- Research
- Medical Physics in Radiology
- X-Ray Imaging and Computed Tomography
- Federated Information Systems
- Translational Molecular Imaging
- Medical Physics in Radiation Oncology
- Biomedical Physics in Radiation Oncology
- Intelligent Medical Systems
- Medical Image Computing
- Radiooncology - Radiobiology
- Smart Technologies for Tumor Therapy
- Radiation Oncology
- Molecular Radiooncology
- Nuclear Medicine
- Translational Radiation Oncology
- Molecular Biology of Systemic Radiotherapy
- Interactive Machine Learning
- Intelligent Systems and Robotics in Urology
- Multiparametric methods for early detection of prostate cancer
- Translational Molecular Imaging in Oncologic Therapy Monitoring
- Molecular Mechanisms of Head and Neck Tumors
- Radiology
- Infection, Inflammation and Cancer
- Tumor Virology
- Pathogenesis of Virus-Associated Tumors
- Immunotherapy and Immunoprevention
- Applied Tumor Biology
- Virotherapy
- Virus-associated Carcinogenesis
- Chronic Inflammation and Cancer
- Microbiome and Cancer
- Experimental Hepatology, Inflammation and Cancer
- Infections and Cancer Epidemiology
- Tumorvirus-specific Vaccination Strategies
- Mammalian Cell Cycle Control Mechanisms
- Molecular Therapy of Virus-Associated Cancers
- DNA Vectors
- Episomal-Persistent DNA in Cancer- and Chronic Diseases
- Cell Biology and Tumor Biology
- Research Groups A-Z
- Junior Research Groups
- Core Facilities
- Center for Preclinical Research
- Chemical Biology Core Facility
- Electron Microscopy
- Flow Cytometry
- Genomics and Proteomics
- Information Technology
- Library
- Kataloge -- Catalogues
- Zeitschriften - Journals
- E-Books - ebooks
- Datenbanken - Databases
- Dokument-Lieferung - Document Delivery
- Publikationsdatenbank - Publication database
- DKFZ Archiv - DKFZ Archive
- Open Access
- Science 2.0
- Ansprechpartner - Contact
- More Information - Service
- Anschrift - Address
- Antiquariat - Second Hand
- Aufstellungssystematik - Shelf Classification
- Ausleihe - Circulation
- Benutzerhinweise - Library Use
- Beschaffungsvorschläge - Desiderata
- Fakten und Zahlen - Facts and Numbers
- Kooperationen, Konsortien - Cooperations, Consortia
- Kopieren, Scannen - Copying, Scans
- Kurse, Führungen - Courses, Introductions
- DKFZ-Intern - internal only
- DEAL-Info
- Light Microscopy
- Omics IT and Data Management Core Facility
- Small Animal Imaging
- Metabolomics Core Technology Platform
- Data Science @ DKFZ
- INFORM
- Baden-Württemberg Cancer Registry
- Cooperations & Networks
- National Cooperations
- International Cooperations
- Cooperational Research Program with Israel: DKFZ - MOST in Cancer Research
- Program
- Members of the Program Committee
- Call
- Publication Database
- German-Israeli Cancer Research Schools
- Archive
- Heidelberg - Israel, Science and Culture
- Symposium 40 Years of German-Israeli Cooperation
- 35th Anniversary Symposium
- 34th Meeting of the DKFZ-MOST Program
- 40th Anniversary Publication
- 30th Anniversary Publication
- 20th Anniversary Publication
- Flyer - The Cancer Cooperation Program
- List Publications 1976-2004
- Highlight-Projects
- Cooperational Research Program with Israel: DKFZ - MOST in Cancer Research
- Cooperations with industrial companies
- DKFZ PostDoc Network
- Cross Program Topic RNA@DKFZ
- Cross Program Topic Epigenetics@dkfz
- Cross Program Topic Single Cell Sequencing
- WHO Collaborating Centers
- DKFZ Site Dresden
- Health + Life Science Alliance Heidelberg Mannheim
Juvenile myelomonocytic leukemia (JMML)
From prognostic biomarkers to understanding molecular mechanisms of the disease

Figure 3: JMML-specific aberrant methylation patterns characterize three distinct JMML subgroups. The heatmap displays the methylation levels for the 1000 most variable JMML-specific differentially methylated probes across 147 patients. The samples are ordered according to methylation group assignment. Clinical annotation for “genotype” (somatic mutations in PTPN11, KRAS, and NRAS, germline or somatic CBL mutations, clinical and/or molecular diagnosis of neurofibromatosis: NF1; quintuple-negative: quint.-neg.; Noonan: clinical and/or molecular diagnosis of Noonan syndrome) and karyotype is depicted on top of the heatmap. Localization of the differentially methylated probes relative to CpG-islands is depicted on the right in grey scale. (from: Lipka et al., Nature Communications 2017; 8(1):2126. doi: 10.1038/s41467-017-02177-w)
© dkfz.de
Juvenile myelomonocytic leukemia (JMML) is a myeloproliferative disorder of early childhood that originates from the multipotent hematopoietic stem and progenitor cell (HSPC) compartment. JMML is characterized by overproduction of mature and immature myeloid cells. Without adequate treatment, survival for most children is less than one year. While few cases show spontaneous remission, allogeneic hematopoietic stem cell transplantation (HSCT) remains the only curative treatment option for the majority of patients. Yet, even with HSCT the 5-year event-free survival still reaches only about 50%.
Hyperactive RAS signaling is assumed to be the main driving event in JMML. It is caused by somatic mutations in KRAS, NRAS, or PTPN11, by biallelic inactivation of NF1 or by biallelic mutations of the CBL gene. In about 90% of all JMML patients, one of these mutations can be detected in the leukemic cells. Recently, less frequent recurrent mutations in JAK3, RAC and RRAS have been identified. These new mutations also result in activation of intracellular signaling pathways including RAS and JAK/STAT signaling. RAS pathway mutations generally occur in a mutually exclusive manner in JMML and co-occurrence has only been described in some cases. Together, the emerging picture of genetic alterations suggests underlying signaling defects involving the RAS pathway in almost all cases of JMML.
So far, there is no clear understanding of how RAS pathway mutations relate to the heterogeneous disease biology and variable clinical outcome seen in JMML patients. Overall, JMML patients with somatic NRAS mutations have a rather favorable disease outcome, whereas patients with somatic PTPN11 mutations appear to represent cases with aggressive biology and are associated with a high risk of relapse after HSCT. However, the affected RAS-pathway gene alone does not fully explain clinical outcome. Evidence from the literature suggested that oncogenic RAS-signaling is able to modify epigenetic patterns.
Using integrative analysis of genome-wide DNA methylation profiles with mutational patterns, copy-number changes and gene-expression in primary JMML samples, we have recently identified three JMML subgroups with unique molecular and clinical characteristics (Figure 3; Lipka et al, Nature Communications 2017; Stieglitz et al., Nature Communications 2017).
Our data indicates that the molecular JMML subgroups might guide clinicians in prospectively identifying those patients who need no or mild cytoreductive treatment only as compared to those patients who have a clear indication for allogeneic stem cell transplantation or those who will qualify for experimental therapies based on their high a priori risk for relapse after transplantation.
The two major goals of our ongoing research are:
- To implement molecular diagnostics into the clinical workup for every JMML patient to perform an up-front risk assessment and to be able to tailor treatment strategies according to assigned risk strata.
- To study the cause and the functional effects of epigenetic dysregulation in JMML using transgenic mouse models and xenotransplantation of primary human JMML cells.